Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL‐286, a novel retinoic acid receptor‐β agonist for treatment of spinal cord injury, in male healthy participants

Overview of attention for article published in British Journal of Clinical Pharmacology, August 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 15 news outlets
blogs: 2 blogs
twitter: 11 X users

wikipedia: 1 Wikipedia page
reddit: 5 Redditors

Readers on

mendeley: 13 Mendeley

So far, Altmetric has seen 12 X posts from 11 X users, with an upper bound of 114,015 followers.

RT @jonathanco43807: Our drug discovery program to develop drugs to treat nerve injury and neurodegeneration has resulted in a top viewed a…

An endogenous signalling system which forms the embryonic nervous system is present in the adult but ligand is missing. Add the drug KCL-286 (https://t.co/zXo37wOPQL…) and reverse aspects of nerve injury and neurodegeneration https://t.co/YMkRzVWx9R

Our drug discovery program to develop drugs to treat nerve injury and neurodegeneration has resulted in a top viewed article at BJCP. Preclinical studies funded @wellcometrust and Clinical studies funded by @The_MRC https://t.co/HPVRnvX2Aa #TopViewedAr…

RT @BritPharmSoc: 💊 'Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.